<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01966575</url>
  </required_header>
  <id_info>
    <org_study_id>H13-02187</org_study_id>
    <nct_id>NCT01966575</nct_id>
  </id_info>
  <brief_title>Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate</brief_title>
  <official_title>Effect of Progestin-Induced Endometrial Shedding on Ovulation Induction Cycles With Clomiphene Citrate: A Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with polycystic ovary syndrome (PCOS) can suffer from infertility because they do not&#xD;
      produce an egg each month, resulting in irregular periods. As a result, these women often&#xD;
      need a medication called clomiphene citrate (clomiphene) to induce ovulation. A traditional&#xD;
      'clomiphene protocol' begins with a short course of progestin treatment to bring on a period&#xD;
      (termed a 'withdrawal bleed') before starting the clomiphene medication. Newer evidence,&#xD;
      however, has suggested that this progestin-induced shedding of the uterine lining (i.e.,&#xD;
      withdrawal bleed) may decrease the chances of pregnancy. The purpose of our study is to&#xD;
      determine whether withdrawal bleeding has an impact on pregnancy rates for patients with PCOS&#xD;
      undergoing a clomiphene cycle.&#xD;
&#xD;
      It is hypothesized that patients who undergo ovulation induction with clomiphene citrate&#xD;
      without prior endometrial shedding will have higher clinical pregnancy rates than those who&#xD;
      begin with a progestin-induced withdrawal bleed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Recent findings suggest that letrozole may be a superior Clomiphene Citrate.&#xD;
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate per ovulation</measure>
    <time_frame>6 weeks after starting clomiphene</time_frame>
    <description>clinical pregnancy rate (gestational sac seen on ultrasound approximately 6-7 weeks after starting clomiphene) per ovulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative pregnancy rate</measure>
    <time_frame>assessed 9 months after the ovulation induction cycles</time_frame>
    <description>cumulative pregnancy rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ovulation rate</measure>
    <time_frame>assessed 1 month after each induced ovulation cycle</time_frame>
    <description>ovulation rate (progesterone &gt;10nmol/L per clomiphene cycle)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ongoing pregnancy rate</measure>
    <time_frame>assessed 12 weeks after clinical pregnancy is acheived</time_frame>
    <description>ongoing pregnancy rate (pregnancy with a fetal heartbeat &gt;12 weeks gestational age)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate</measure>
    <time_frame>Assessed 4 months after clinical pregnancy acheived</time_frame>
    <description>miscarriage rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>multiple pregnancy rate</measure>
    <time_frame>Assessed 4 months after clinical pregnancy acheived</time_frame>
    <description>multiple pregnancy rate (twins and higher order multiples)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness</measure>
    <time_frame>Assessed at 1 month after conception</time_frame>
    <description>endometrial thickness (assessed via transvaginal ultrasound)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>No withdrawal bleed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No progestin prior to ovulation induction with clomiphene citrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withdrawal Bleed</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progestin</intervention_name>
    <description>The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.</description>
    <arm_group_label>No withdrawal bleed</arm_group_label>
    <other_name>medroxyprogesterone acetate (MPA), i.e. Provera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Polycystic ovary syndrome (Rotterdam 2003 Consensus Criteria) and a diagnosis of&#xD;
             anovulatory infertility&#xD;
&#xD;
          -  Age 18-38 years&#xD;
&#xD;
          -  At least 1 patent fallopian tube (as demonstrated by hysterosalpingogram,&#xD;
             hydrotubation or hysterosonogram within the last year)&#xD;
&#xD;
          -  Normal semen analysis (total motile sperm count &gt;20million/ml)&#xD;
&#xD;
          -  Normal uterine cavity (as demonstrated by hysterosalpingogram, hydrotubation or&#xD;
             hysterosonogram within the last year)&#xD;
&#xD;
          -  Undergoing ovulation-induction with clomiphene citrate without intra-uterine&#xD;
             insemination (IUI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &lt; 17 kg/m2 or &gt; 40 kg/m2&#xD;
&#xD;
          -  Prior treatment with clomiphene citrate&#xD;
&#xD;
          -  Presence of a hydrosalpinx (as seen on ultrasound, hysterosalpingogram, hydrotubation&#xD;
             or hysterosonogram)&#xD;
&#xD;
          -  Those with systemic disease such as diabetes mellitus, uncontrolled thyroid disease,&#xD;
             systemic lupus erythematosus and antiphospholipid antibody syndrome&#xD;
&#xD;
          -  Any other cause of infertility other than anovulation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Havelock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Centre for Reproductive Medicine</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2013</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Progestin</keyword>
  <keyword>Endometrial shedding</keyword>
  <keyword>Ovulation induction cycles</keyword>
  <keyword>Clomiphene citrate</keyword>
  <keyword>Clinical pregnancy rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

